1. Field of the Disclosure
A variety of devices and techniques exist for the manipulation of fluids in hospitals and medical settings, and in particular the selective facilitation of fluid movement to or from patients or to or from a fluid flow line. Fluid flow lines rely on a variety of connectors to help develop preferred flow characteristics or access points. Many connectors include check valves.
2. Description of the Related Art
Current fluid flow systems, medical connectors, and check valves have various limitations and disadvantages and a need exists for further improvement.
A variety of fluid flow lines and systems are used in hospitals and medical settings for the selective facilitation of fluid movement to or from patients. For example, central venous catheters can be used to administer IV fluids, various medications or blood products, and/or parenteral nutrition. In some embodiments, medical connectors can be provided on one end of a flow line to allow for periodic access to a flow line or for application of different inputs to the flow line. Generally, these structures require valves to allow fluid to enter the main flow line while preventing retrograde flow.
In certain situations, it may be desirable to provide multiple connections to a flow line into a patient's blood stream. This can allow for easy connection to multiple fluid or medication sources. This is particularly useful in treatments that require multiple inputs, such as chemotherapy. When multiple connections are desired, a manifold, extension set, or other multi-input structure can be used. These structures also require valves to allow fluid to enter the main flow line but that preferably prevent retrograde flow. In various embodiments described herein, such valves can be designed to maximize efficiency and desired flow rates and flow characteristics while still providing a check on retrograde flow. In some situations, it may be desirable to provide a single connection point with one way flow.
In various embodiments, a medical check valve for use in a medical device to provide one-way fluid flow between a first fluid location and a second fluid location can include a flexible diaphragm having a top surface, a bottom surface, and a side wall between the top surface and the bottom surface, and a first support member extending from the bottom surface of the flexible diaphragm and a second support member extending from the bottom surface of the flexible diaphragm, the first support member and second support member positioned to define a line of or axis of symmetry that bisects the bottom surface without passing through the first support member or the second support member. The flexible diaphragm can have a first position in which the top surface is generally planar and is configured to seal against a fluid opening and a second position in which the top surface of the diaphragm is curved generally around the line of symmetry and is configured to be displaced from the fluid opening.
In some embodiments, the line of symmetry can be the only line of symmetry that bisects the bottom surface without passing through the first support member or the second support member. In some embodiments, the flexible diaphragm can be a disc. In some embodiments, the support members can be positioned 180 degrees apart about the disc. In some embodiments, the flexible diaphragm can be nonperforate. In some embodiments, the flexible diaphragm, the first support member, and the second support member can be integrally formed and/or molded into a single unitary piece.
In some embodiments, the diaphragm can be configured to move from the first position to the second position at varying amounts of pressure. For example, in some embodiments a net pressure of less than 3 psi on the top surface of the flexible diaphragm is sufficient to move the diaphragm from the first position to the second position. In some embodiments, a net pressure of less than 1 psi on the top surface of the flexible diaphragm is sufficient to move the diaphragm from the first position to the second position. In some embodiments, a positive net pressure on the bottom surface of the flexible diaphragm is needed to maintain the flexible diaphragm in the first position.
In various embodiments, a medical manifold for use in providing access to a fluid flow path can include a housing having a first port, a second port, a first channel connecting the first port and the second port and defining a first flow path, and a third port having a recess in an outer wall of the housing and a second channel fluidly connecting the recess and the first flow path. The manifold can also include a valve member having a diaphragm and a plurality of support members configured to be positioned in the recess to thereby define a space between a bottom wall of the recess and the diaphragm. The manifold can also include a medical connector configured to attach to the third port, wherein the valve member in a closed position is configured to seal against an opening into the medical connector and the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member, through the second channel, and into the first flow path.
In some embodiments, an outer wall of the recess can be cylindrical. In some embodiments, an outer wall of the recess can include multiple walls. In some embodiments, the third port can have at least two projections extending from the bottom wall of the recess and adjacent the second channel, wherein the projections define an outer channel between the projections and an outer wall of the recess and at least two transverse channels between the projections. In some embodiments, the plurality of support members can be configured to be positioned on at least two of the projections. In such embodiments, the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member to the outer channel, through the transverse channels, and into the second channel.
In some embodiments, the valve member can be biased toward the closed position. In some embodiments, the valve member can be configured to move from the closed to the open position as a result of pressure from fluid in the medical connector. In some embodiments, the housing can be monolithic. In some embodiments, a net pressure of less than 3 psi on the valve member can be sufficient to move the valve member from the closed position to the open position.
In various embodiments, a medical manifold for use in providing access to a fluid flow path can include a first port, a second port, a first channel connecting the first port and the second port and defining a first flow path, and a housing having a third port in an outer wall of the housing and a second channel fluidly connecting the third port and the first flow path. The manifold can also include a valve member having a diaphragm and a plurality of support members configured to be positioned in the third port to thereby define a space between a bottom wall of the third port and the diaphragm. The manifold can also include a medical connector configured to attach to the third port, wherein the valve member in a closed position is configured to seal against an opening into the medical connector and the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member, through the second channel, and into the first flow path.
In some embodiments, the third port further includes at least two projections extending from the bottom wall of the third port and adjacent the second channel, wherein the projections define at least two transverse channels between the projections. The plurality of support members may be configured to be positioned on at least two of the projections. In some embodiments, the third port of the medical manifold includes a recess and the projections extend from the bottom wall of the recess. A wall surrounding the recess may extend outward from the housing and a portion of the medical connector may be configured to surround at least a portion of the wall. In some embodiments, the medical connector is sonically welded to the third port.
In some embodiments, an outer wall of the third port can be cylindrical. In some embodiments, an outer wall of the third port can include multiple walls. In some embodiments, the third port can have at least two projections extending from the bottom wall of the third port and adjacent the second channel, wherein the projections define an outer channel between the projections and an outer wall of the third port and at least two transverse channels between the projections. In some embodiments, the plurality of support members can be configured to be positioned on at least two of the projections. In such embodiments, the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member to the outer channel, through the transverse channels, and into the second channel.
In various embodiments, a medical manifold for use in providing access to a fluid flow path can include a first port, a second port, a first channel connecting the first port and the second port and defining a first flow path, and a housing having a third port in an outer wall of the housing and a second channel fluidly connecting the third port and the first flow path. The manifold can also include a valve member having a diaphragm and a plurality of support members configured to be positioned in the third port to thereby define a space between a bottom wall of the third port and the diaphragm. The manifold can also include a medical connector configured to attach to the third port, wherein the valve member in a closed position is configured to seal against an opening into the medical connector and the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member, through the second channel, and into the first flow path. The medical manifold can also include a second housing including a fourth port with a third channel fluidly connecting the fourth port and the first flow path. In some embodiments, the manifold can include a second valve member with a diaphragm and a plurality of support members configured to be positioned in the fourth port to thereby define a space between a bottom wall of the fourth port and the diaphragm. Some manifolds can include a second medical connector configured to attach to the fourth port, wherein the second valve member in a closed position is configured to seal against an opening into the second medical connector and the second valve member in an open position is configured to allow fluid to flow from the second medical connector, past the second valve member, through the third channel, and into the first flow path. In some embodiments, the first and second housings are monolithic while in other embodiments, wherein the first and second housings are joined by a flexible connecting element.
With reference to the attached figures, certain embodiments and examples of fluid flow systems, medical connectors, and valves will now be described. Various embodiments of check valves described herein are with reference to a manifold or extension set, but they are not so limited. In some aspects, they can be applied to any system to provide for one-way flow between a medical connector and a fluid flow line, such as in, for example, IV sets, stopcocks or other branched connectors including y-site connectors, and other systems. As used herein, the term “fluid” refers to either gases or liquids.
In some embodiments, a first port 20 can have a threaded end 22 that can be used to connect to a threaded medical connector. In some embodiments, a second port 30 can have a male luer lock 32, including a tapered cannula 34 (visible in
In some embodiments, the manifold 10 can include a plurality of access ports 40, described and illustrated in more detail below. The access ports can be adapted to connect or attach to a variety of types of medical connectors 50. In some embodiments, as illustrated, a medical connector 50 can be a needleless connector. In the illustrated embodiment, the manifold includes six medical connectors 50, three on a first side of the manifold and three on a second side of the manifold.
In various embodiments, a manifold can have varying numbers of access ports and medical connectors. For example,
Other combinations of ports are also possible. For example,
Embodiments of the invention may provide various ways to connect medical connectors to the housing ports, as discussed in greater detail below. For example,
As shown, in some embodiments various modifications can be made to the connecting portions or joints 16 between the ports. For example,
In some embodiments, various ports may remain connected or unconnected to one or more fluid sources and/or to a patient. For example, in some embodiments, one of the first port 20 and second port 30 can be connected to a patient, the other of the first port and second port may be sealed (such as with a medical connector 50 or a similar sealed access port) and unconnected to a fluid source, and one or more of the medical connectors 50 can be connected to a fluid source for the patient. In some embodiments, embodiments of the manifold can be used without a patient, for example, to combine one or more fluids into a single fluid receptacle (not shown). Accordingly, embodiments of the invention need not be used in direct connection with a patient.
In some embodiments, other types of medical connectors or of needleless medical connectors can be attached to the access ports 40 of the manifolds. These can include connectors configured to receive syringes and connectors of varying designs. In some embodiments, a manifold can include one or more of a first type of medical connector and one or more of a second type of medical connector. In some embodiments, a manifold can include more than two types of medical connectors. In some embodiments, first port 20 and/or second port 30 may include sealed access ports that are similar to those that may be used for access ports 40. Similarly, they can include check valves such as those described herein.
Medical connectors can be attached to the housings in a variety of ways. As shown in
Preferably, the medical connectors 50 can each provide a fluid flow path from a medical implement attached to the medical connector, through the medical connector, into the access port 40 and through an access channel 42 into a main channel 14 of the manifold. In a similar fashion, medical connectors 50′ can each provide a fluid flow path from a medical implement attached to the medical connector, through the medical connector, and into the access port 40′ and through an access channel 42′ into a main channel 14 of the manifold. Preferably, the access port 40 or 40′ can include a one-way valve or check valve 100, which can allow fluid to flow through the medical connector into the main channel 14, but prevent fluid from flowing from the main channel back into the medical connector. Various embodiments of a check valve 100 are described in more detail below.
Preferably, the outer walls 156 of the protrusion do not extend all the way to the outer wall 142 of the access port recess 140, thereby defining an outer channel 48 between the protrusions and the outer wall 142. The protrusions can be spaced from each other to define transverse channels 46 between them that can connect the outer channel 48 to the access channel 42. In some embodiments, the access port 40 can also include an outer recess 44 that can be used to help seat a medical connector attached to the access port.
In some embodiments, various components of the access port 40 can be centered around the access channel 42. In some embodiments, the access channel itself can be generally cylindrical and have a radius R1, as illustrated. In some embodiments the outer wall 142 of the access port recess 140 can have a radius R3 centered on the center of the access channel 42. Similarly, the outer walls 156 of the protrusions 150 can be curved and have a radius of curvature R2 centered on the center of the access channel 42. Similar radius of curvatures may be defined by access port 40′. In the illustrated embodiment, R2′ and R3′ of access port 40′ would be equal.
When fluid flows through a medical connector attached to an access port 40, it will flow through the channels of the access port in order to reach a main channel of a fluid flow line. In various embodiments, the sizing of certain components of the access port can affect the size of the outer channel 48, transverse channels 46, and/or access channel 42, and therefore can affect the fluid flow characteristics of the access port 40.
Thus, for example, in some embodiments the ratio of the radius R3 of the access port recess 140 to the radius R2 of the outer walls 156 of protrusions 150 may vary. In some embodiments, the ratio of R3 to R2 can be between approximately 0.5 and 2.0. In some embodiments, the ratio of R3 to R2 can be between approximately 0.8 and 1.7. In some embodiments, the ratio of R3 to R2 can be between approximately 1.0 and 1.5. In some embodiments, the ratio of R3 to R2 can be between approximately 1.1 and 1.3. These ratios are also applicable to access port 40′.
Similarly, in some embodiments the ratio of the radius R3 of the access port recess 140 to the radius R1 of the access channel 42 may vary. In some embodiments, the ratio of R3 to R1 can be between approximately 2.0 and 3.3. In some embodiments, the ratio of R3 to R1 can be between approximately 2.3 and 3.0. In some embodiments, the ratio of R3 to R1 can be between approximately 2.5 and 2.8. In some embodiments, the ratio of R3 to R1 can be between approximately 2.6 and 2.7. These ratios are also applicable to access port 40′.
Further, in some embodiments the ratio of the radius R2 of the outer walls 156 of protrusions 150 to the radius R1 of the access channel 42 may vary. In some embodiments, the ratio of R2 to R1 can be between approximately 1.5 and 2.9. In some embodiments, the ratio of R2 to R1 can be between approximately 1.8 and 2.6. In some embodiments, the ratio of R2 to R1 can be between approximately 2.1 and 2.3. These ratios are also applicable to access port 40′.
The supports can have an outer wall 122 that is preferably flush with and forms a continuous surface with the side wall 114 of the diaphragm. In some embodiments, however, the supports 120 can be inset from the side wall 114 such that there is a portion of the bottom surface 112 between the supports 120 and the side wall 114.
In some embodiments, as illustrated, the supports 120 can be positioned approximately 180 degrees apart about the center of the valve. The valve can have an axis of symmetry 2 that bisects the valve and does not pass through either support, as illustrated. In some embodiments, the valve can have more than two supports 120, with pairs positioned approximately 180 degrees apart from each other. For example, a valve could have four supports, each 90 degrees apart, and multiple axes of symmetry that bisect the valve and do not pass through any of the supports. In some embodiments, the axis of symmetry can define how the valve deforms if it experiences a pressure differential between its bottom surface 112 and its top surface 116. For example, in the illustrated embodiment, a positive net pressure on the top surface of the valve member would cause the valve member to bend, buckle, or curve generally about the axis of symmetry or an axis that is parallel to the axis of symmetry.
In some embodiments, the supports 120 can all be positioned the same minimum distance R5 from the center of the valve. In some embodiments, one or more of the supports can have a different minimum distance from the center of the valve than one or more of the other supports, in which case R5 can refer to the minimum distance from the center of the valve to the closest support 120. In some embodiments, the relationship between the distance R5 and R4 can affect how easily the valve member deforms as a result of differential pressures on the top surface 116 and bottom surface 112 of the diaphragm 110. In some embodiments, for example, the ratio of R4 to R5 can be between approximately 1.2 and approximately 1.8. In some embodiments, the ratio of R4 to R5 can be between approximately 1.3 and approximately 1.6. In some embodiments, the ratio of R4 to R5 can be between approximately 1.3 and approximately 1.5. In some embodiments, the ratio of R4 to R5 can be between approximately 1.35 and approximately 1.45. In some embodiments, the ratio of R4 to R5 can be greater than 1.8 or less than 1.2.
In some embodiments, the ratio of the width w2 to the height h1 of the supports can affect how easily and how much the diaphragm 110 can bend when the valve is in an open position, discussed below. This can also affect the ability of the valve to handle high flow rates and/or how quickly the valve opens to allow fluid flow. In some embodiments, the ratio of the width w2 to the height h1 can be between approximately 3 and approximately 8. In some embodiments, the ratio of the width w2 to the height h1 can be between approximately 4 and approximately 7. In some embodiments, the ratio of the width w2 to the height h1 can be between approximately 4.5 and approximately 6.5. In some embodiments, the ratio of the width w2 to the height h1 can be between approximately 5 and approximately 6.
FIG.11A illustrates a valve 100 positioned within an access port 40, as described above. The supports 120 can be positioned on the protrusions 150 to lift the diaphragm above the protrusions. In some embodiments, the access port recess 140 can have no protrusions and the supports of the valve can be positioned directly on the base 144 of the recess or on the base of any recessed portion of a flow channel. Thus, for example, in some embodiments the valve can be positioned within an inlet and/or an outlet port of a manifold, extension set, or other connection systems. In some embodiments, the valve can be positioned within a medical connector that has only a single inlet and outlet port.
In some embodiments, the medical connector 50 and/or the access port 40 can be sized and configured such that the base 70 of the medical connector or the ring 74 can compress at least a portion of the valve 100. This can help create the seal between the diaphragm 110 and the medical connector. Thus, in embodiments where the diaphragm seals against a ring 74 or other projection of the medical connector, the height h2 (shown in
In various embodiments, the relationship between the radius R6 of a ring 74 (shown in
If a negative pressure differential exists on the diaphragm between the bottom surface 112 and the upper or top surface 116—i.e., a net negative pressure on the top surface—the pressure will tend to push the diaphragm against the base 70 or inner annular projection 74, which can create or enhance a seal and prevent fluid from flowing into the medical connector. In contrast, if there is a positive pressure differential—i.e., a positive net pressure on the top surface 116—the diaphragm 110 will tend to deform as described above and move the valve from a closed to an open position, as illustrated in
In some embodiments, at least a portion of the valve member 100 remains stationary as the valve transitions between an open and closed position. This can help the valve move more easily from an open to a closed position to help prevent undesired retrograde flows. It can also allow for designs that transition from a closed to an open position at lower pressures, as described further below. In some embodiments, at least a portion of the diaphragm can remain in generally the same location when the valve is in an open position as when the valve is in a closed position. In some embodiments, at least a portion of the diaphragm 110 can remain in contact with the base 70 of a medical connector when the valve is in the open position.
In some embodiments, the valve 100 can be formed of a resilient material such that, absent a pressure differential, the valve tends to move toward the closed position (i.e., is biased toward the closed position).
As described above, the valve can be designed differently to affect how easily it moves from a closed to an open position. The pressure differential required to move the valve 100 from a closed to an open position can be referred to as the cracking pressure. In some embodiments, the valve can have a minimal cracking pressure, such that the valve very easily transitions from a closed to an open position. This can make it easier to pass fluids through the valve and into a main fluid flow line. It also allows the valves to work effectively with high flow rate connectors (such as, for example, connectors that allow flow rates of 450 mL/min or even greater). In some embodiments, the valve can have a cracking pressure that is at or below approximately 5 psi. In some embodiments, the valve can have a cracking pressure that is at or below approximately 4 psi. In some embodiments, the valve can have a cracking pressure that is at or below approximately 3 psi. In some embodiments, the valve can have a cracking pressure that is at or below approximately 2 psi. In some embodiments, the valve can have a cracking pressure that is at or below approximately 1 psi. In some embodiments, the valve can have a cracking pressure that is less than the pressure exerted on the valve from fluid in a reservoir hanging on a standard IV pole. In some embodiments, this can be approximately equal to the pressure of 36 inches of water. In some embodiments, this can be approximately equal to 1.3 psi.
In some embodiments, the cracking pressure can be zero, such that even with zero pressure differential between the lower 112 and upper 116 surfaces of the diaphragm 110 the valve will be in an open position. In other words, in some embodiments the closed position of the valve is not an equilibrium position of the valve. In such embodiments, the valve may not be in a closed position until a retrograde fluid flow creates a negative pressure differential on the diaphragm 110. In some embodiments with a zero cracking pressure, the valve can function as a floating check valve, as described, for example, above.
As described above, in some embodiments the medical connector 50 can be a needleless connector that has a base 70, a body 60, and a connector valve member 80. The base can also include an internal projection 90 that is within the body 60. A cannula 202 of the medical implement can compress the connector valve member 80 into an open position, exposing an opening 92 in the internal projection through which fluid in the cannula can pass. Once within the internal projection, the fluid can flow into the access port recess 140, through the access channel 42, and into the main flow channel 14. Similar activation can occur with medical connector 50′.
In some embodiments, one or more components of the devices and elements described herein can be translucent, transparent, and/or clear such that the fluid flow path through the components is visible. These components can include, for example, the housing 12 of a manifold, the medical connector 50 (including the body 60, base 70, and/or valve member 80), the medical connector 50′ (including the body 60′, base 70′, and/or valve member 80′), and/or the check valve 100. Additionally, in some embodiments one or more components can include elements configured or adapted to kill pathogens. For example, in some embodiments one or more of the valves 80, 80′, or 100 can include antimicrobial agents. In some embodiments, the antimicrobial agents can be a coating or can be incorporated into the structure of the components, from where they can leach out, such as from a silicone matrix of a valve.
The terms “approximately”, “about”, and “substantially” as used herein represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount.
Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while a number of variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above.
Similarly, this method of disclosure is not to be interpreted as reflecting an intention that any claim require more features than are expressly recited in that claim. Rather, inventive aspects may lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following the Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment.
This application is a continuation of PCT/US2014/068455, filed Dec. 3, 2014, titled CHECK VALVE, which claims the benefit of U.S. Provisional Application No. 61/914,892, filed Dec. 11, 2013, titled CHECK VALVE, the entire contents of each are incorporated by reference herein and made a part of this specification.
Number | Name | Date | Kind |
---|---|---|---|
274447 | Kennish | Mar 1883 | A |
1578517 | Hein | Mar 1926 | A |
1923501 | Perry | Aug 1933 | A |
2210098 | Ravenscroft | Aug 1940 | A |
2289677 | Perelson | Jul 1942 | A |
2577780 | Lockhart | Dec 1951 | A |
2756282 | Deane | Jul 1956 | A |
2756740 | Deane | Jul 1956 | A |
2809665 | Crowe | Oct 1957 | A |
2847995 | Adams | Aug 1958 | A |
2999499 | Willet | Sep 1961 | A |
3134380 | Armao | May 1964 | A |
3135261 | Carroll | Jun 1964 | A |
3171412 | Braun | Mar 1965 | A |
3176021 | Volungis et al. | Mar 1965 | A |
3191655 | McCord | Jun 1965 | A |
3193154 | Bross et al. | Jul 1965 | A |
3334860 | Bolton, Jr. | Aug 1967 | A |
3352531 | Kilmarx | Nov 1967 | A |
3354881 | Bloch | Nov 1967 | A |
3385301 | Harautuneian | May 1968 | A |
3502097 | Muller | Mar 1970 | A |
3534771 | Eyerdam et al. | Oct 1970 | A |
3570484 | Steer et al. | Mar 1971 | A |
3630199 | Gangarosa | Dec 1971 | A |
3648684 | Barnwell et al. | Mar 1972 | A |
3659602 | Cloyd | May 1972 | A |
3717174 | Dewall | Feb 1973 | A |
3726282 | Patel | Apr 1973 | A |
3788519 | Mengel | Jan 1974 | A |
3830241 | Dye et al. | Aug 1974 | A |
3831629 | Mackal et al. | Aug 1974 | A |
3852385 | Huggins | Dec 1974 | A |
3861388 | Vaughn | Jan 1975 | A |
3889675 | Stewart | Jun 1975 | A |
3896853 | Bernhard | Jul 1975 | A |
3965910 | Fisher | Jun 1976 | A |
3974832 | Kruck | Aug 1976 | A |
3976063 | Henneman et al. | Aug 1976 | A |
3976073 | Quick et al. | Aug 1976 | A |
3977403 | Patel | Aug 1976 | A |
3986508 | Barrington | Oct 1976 | A |
3993063 | Larrabee | Nov 1976 | A |
3994293 | Ferro | Nov 1976 | A |
4005710 | Zeddies et al. | Feb 1977 | A |
4019512 | Tenczar | Apr 1977 | A |
4022205 | Tenczar | May 1977 | A |
4040420 | Speer | Aug 1977 | A |
4076285 | Martinez | Feb 1978 | A |
4079738 | Dunn et al. | Mar 1978 | A |
4080965 | Phillips | Mar 1978 | A |
4121585 | Becker, Jr. | Oct 1978 | A |
4128098 | Bloom et al. | Dec 1978 | A |
4133441 | Mittleman et al. | Jan 1979 | A |
4143853 | Abramson | Mar 1979 | A |
4149535 | Volder | Apr 1979 | A |
4161949 | Thanawalla | Jul 1979 | A |
4186775 | Muroi | Feb 1980 | A |
4187846 | Lolachi et al. | Feb 1980 | A |
4191183 | Mendelson | Mar 1980 | A |
4198983 | Becker et al. | Apr 1980 | A |
4200096 | Charvin | Apr 1980 | A |
4214779 | Losell | Jul 1980 | A |
4219912 | Adams | Sep 1980 | A |
4243034 | Brandt | Jan 1981 | A |
4257416 | Prager | Mar 1981 | A |
D259278 | McCaw et al. | May 1981 | S |
4294249 | Sheehan et al. | Oct 1981 | A |
4294250 | Dennehey | Oct 1981 | A |
4296949 | Muetterties et al. | Oct 1981 | A |
4306705 | Svensson | Dec 1981 | A |
D263871 | Matsuura | Apr 1982 | S |
4324239 | Gordon et al. | Apr 1982 | A |
4328802 | Curley et al. | May 1982 | A |
4329987 | Rogers et al. | May 1982 | A |
4334551 | Pfister | Jun 1982 | A |
4338933 | Bayard et al. | Jul 1982 | A |
4342315 | Jackson | Aug 1982 | A |
4346703 | Dennehey et al. | Aug 1982 | A |
4362156 | Feller et al. | Dec 1982 | A |
4387879 | Tauschinski | Jun 1983 | A |
RE31315 | Jenkins et al. | Jul 1983 | E |
4392851 | Elias | Jul 1983 | A |
4405163 | Voges et al. | Sep 1983 | A |
4405312 | Gross et al. | Sep 1983 | A |
4411662 | Pearson | Oct 1983 | A |
4417890 | Dennehey et al. | Nov 1983 | A |
4421296 | Stephens | Dec 1983 | A |
4429856 | Jackson | Feb 1984 | A |
4432759 | Gross et al. | Feb 1984 | A |
4432765 | Oscarsson | Feb 1984 | A |
4439188 | Dennehey et al. | Mar 1984 | A |
4439193 | Larkin | Mar 1984 | A |
4449693 | Gerea | May 1984 | A |
4457749 | Bellotti et al. | Jul 1984 | A |
4483368 | Panthafer | Nov 1984 | A |
4508367 | Oreopoulos et al. | Apr 1985 | A |
4511359 | Vaillancourt | Apr 1985 | A |
4512766 | Vaillancourt | Apr 1985 | A |
4535820 | Raines | Aug 1985 | A |
4556086 | Raines | Dec 1985 | A |
4564054 | Gustavsson | Jan 1986 | A |
4566480 | Parham | Jun 1986 | A |
4592356 | Guiterrez | Jun 1986 | A |
4607868 | Harvey et al. | Aug 1986 | A |
4610469 | Wolff-Mooij | Sep 1986 | A |
4617012 | Vaillancourt | Oct 1986 | A |
4619640 | Poholshy et al. | Oct 1986 | A |
4623068 | Brown et al. | Nov 1986 | A |
4645494 | Lee et al. | Feb 1987 | A |
4666429 | Stone | May 1987 | A |
4673400 | Martin | Jun 1987 | A |
4676228 | Krasner et al. | Jun 1987 | A |
4683916 | Raines | Aug 1987 | A |
4706487 | Bandou et al. | Nov 1987 | A |
4710168 | Schwab et al. | Dec 1987 | A |
4725267 | Vaillancourt | Feb 1988 | A |
4730635 | Linden | Mar 1988 | A |
4752292 | Lopez et al. | Jun 1988 | A |
D296592 | Wellenstam | Jul 1988 | S |
4758224 | Siposs | Jul 1988 | A |
4759756 | Forman et al. | Jul 1988 | A |
4775369 | Schwartz | Oct 1988 | A |
4778447 | Velde et al. | Oct 1988 | A |
4778453 | Lopez | Oct 1988 | A |
4781702 | Herrli | Nov 1988 | A |
4804015 | Albinsson | Feb 1989 | A |
D300177 | Bellotti et al. | Mar 1989 | S |
D300361 | Tokarz | Mar 1989 | S |
4810241 | Rogers et al. | Mar 1989 | A |
4813938 | Raulerson | Mar 1989 | A |
4819684 | Zaugg et al. | Apr 1989 | A |
4832214 | Schrader et al. | May 1989 | A |
4834664 | Lin | May 1989 | A |
4834716 | Ogle, II | May 1989 | A |
D303013 | Konopka | Aug 1989 | S |
4871353 | Thomsen | Oct 1989 | A |
4874377 | Newgard et al. | Oct 1989 | A |
4878897 | Katzin | Nov 1989 | A |
4880414 | Whipple | Nov 1989 | A |
4889527 | Herrli | Dec 1989 | A |
4908018 | Thomsen | Mar 1990 | A |
4915687 | Sivert | Apr 1990 | A |
4917668 | Haindl | Apr 1990 | A |
4919167 | Manska | Apr 1990 | A |
4928212 | Benavides | May 1990 | A |
4934657 | Dodson | Jun 1990 | A |
4943896 | Johnson | Jul 1990 | A |
4946445 | Lynn | Aug 1990 | A |
4946448 | Richmond | Aug 1990 | A |
4963133 | Whipple | Oct 1990 | A |
4964855 | Todd et al. | Oct 1990 | A |
4966199 | Ruschke | Oct 1990 | A |
4969883 | Gilbert et al. | Nov 1990 | A |
D314050 | Sone | Jan 1991 | S |
4985399 | Matsuda et al. | Jan 1991 | A |
4987181 | Bichon et al. | Jan 1991 | A |
4991413 | Arnalda | Feb 1991 | A |
4991629 | Ernesto et al. | Feb 1991 | A |
4998713 | Vaillancourt | Mar 1991 | A |
4998927 | Vaillancourt | Mar 1991 | A |
5006114 | Rogers et al. | Apr 1991 | A |
5009490 | Kuono et al. | Apr 1991 | A |
5018532 | Ethridge, III | May 1991 | A |
5024657 | Needham et al. | Jun 1991 | A |
5031675 | Lindqren | Jul 1991 | A |
5041087 | Loo et al. | Aug 1991 | A |
5046456 | Heyman et al. | Sep 1991 | A |
5049128 | Duquette | Sep 1991 | A |
D321250 | Jepson et al. | Oct 1991 | S |
D321251 | Jepson et al. | Oct 1991 | S |
5061253 | Yoshida | Oct 1991 | A |
5064416 | Newgard | Nov 1991 | A |
5065783 | Ogle, II | Nov 1991 | A |
5071411 | Hillstead | Dec 1991 | A |
5098385 | Walsh | Mar 1992 | A |
5098405 | Peterson et al. | Mar 1992 | A |
5098406 | Sawyer | Mar 1992 | A |
5100394 | Dudar et al. | Mar 1992 | A |
5108380 | Heritze et al. | Apr 1992 | A |
5114408 | Fleischhaker et al. | May 1992 | A |
5116361 | Kim et al. | May 1992 | A |
5122123 | Vaillancourt | Jun 1992 | A |
5125915 | Berry et al. | Jun 1992 | A |
5135489 | Jepson et al. | Aug 1992 | A |
5137524 | Lynn et al. | Aug 1992 | A |
5147333 | Raines | Sep 1992 | A |
5154703 | Bonaldo | Oct 1992 | A |
5158554 | Jepson et al. | Oct 1992 | A |
5163922 | McElveen, Jr. et al. | Nov 1992 | A |
5167238 | Newman | Dec 1992 | A |
5167636 | Clement | Dec 1992 | A |
5171234 | Jepson et al. | Dec 1992 | A |
5180761 | Shiao | Jan 1993 | A |
5188620 | Jepson et al. | Feb 1993 | A |
5190067 | Paradis et al. | Mar 1993 | A |
5199947 | Lopez et al. | Apr 1993 | A |
5201717 | Wyatt et al. | Apr 1993 | A |
5201722 | Moorehead et al. | Apr 1993 | A |
5203775 | Frank et al. | Apr 1993 | A |
5211638 | Dudar et al. | May 1993 | A |
5215538 | Larkin | Jun 1993 | A |
5221271 | Nicholson et al. | Jun 1993 | A |
5224515 | Foster et al. | Jul 1993 | A |
5242393 | Brimhall et al. | Sep 1993 | A |
5242423 | Goodsir et al. | Sep 1993 | A |
5242425 | Whine et al. | Sep 1993 | A |
5242432 | DeFrank | Sep 1993 | A |
5251873 | Atkinson et al. | Oct 1993 | A |
5253842 | Huebscher et al. | Oct 1993 | A |
5255676 | Russo | Oct 1993 | A |
5256155 | Yerlikaya et al. | Oct 1993 | A |
5267966 | Paul | Dec 1993 | A |
5269771 | Thomas et al. | Dec 1993 | A |
5273533 | Bonaldo | Dec 1993 | A |
5280876 | Atkins | Jan 1994 | A |
D344585 | Morse | Feb 1994 | S |
5284475 | Mackal | Feb 1994 | A |
5290254 | Vaillancourt | Mar 1994 | A |
5292308 | Ryan | Mar 1994 | A |
5293902 | Lapierie | Mar 1994 | A |
5295657 | Atkinson | Mar 1994 | A |
5295658 | Atkinson et al. | Mar 1994 | A |
5301686 | Newman | Apr 1994 | A |
5306265 | Ragazzi | Apr 1994 | A |
5312083 | Ekman | May 1994 | A |
5312377 | Dalhon | May 1994 | A |
5322518 | Schneider | Jun 1994 | A |
5324270 | Kayon et al. | Jun 1994 | A |
5336192 | Palestrant | Aug 1994 | A |
5342316 | Wallace | Aug 1994 | A |
5342326 | Peppel et al. | Aug 1994 | A |
5344414 | Lopez et al. | Sep 1994 | A |
5348542 | Ellis | Sep 1994 | A |
5353837 | Faust | Oct 1994 | A |
5356375 | Higley | Oct 1994 | A |
5356396 | Wyatt et al. | Oct 1994 | A |
5360413 | Leason et al. | Nov 1994 | A |
5380306 | Brinon | Jan 1995 | A |
5389086 | Attermeier et al. | Feb 1995 | A |
5398530 | Derman | Mar 1995 | A |
5401245 | Haining | Mar 1995 | A |
D357736 | Dye | Apr 1995 | S |
5402826 | Molnar et al. | Apr 1995 | A |
5402982 | Atkinson et al. | Apr 1995 | A |
5407437 | Heimreid | Apr 1995 | A |
5409471 | Atkinson et al. | Apr 1995 | A |
5395348 | Ryan | May 1995 | A |
5411483 | Loomas et al. | May 1995 | A |
5411499 | Dudar et al. | May 1995 | A |
5417673 | Gordon | May 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5439452 | McCarty | Aug 1995 | A |
5441487 | Vedder | Aug 1995 | A |
5442941 | Kahonen et al. | Aug 1995 | A |
5456676 | Nelson et al. | Oct 1995 | A |
5462255 | Rosen et al. | Oct 1995 | A |
D363988 | Dye | Nov 1995 | S |
D364459 | Dye | Nov 1995 | S |
D364460 | Dye | Nov 1995 | S |
D364680 | Dye | Nov 1995 | S |
5465938 | Werge | Nov 1995 | A |
5470319 | Mayer | Nov 1995 | A |
5474544 | Lynn | Dec 1995 | A |
5480393 | Bommarito | Jan 1996 | A |
5487731 | Denton | Jan 1996 | A |
D367714 | Pennicook | Mar 1996 | S |
5501426 | Atkinson et al. | Mar 1996 | A |
5501526 | Asai et al. | Mar 1996 | A |
D368737 | Dunn et al. | Apr 1996 | S |
5509433 | Paradis | Apr 1996 | A |
5514116 | Vaillancourt et al. | May 1996 | A |
5520665 | Fleetwood | May 1996 | A |
5522804 | Lynn | Jun 1996 | A |
5533708 | Atkinson et al. | Jul 1996 | A |
5533996 | Murphey et al. | Jul 1996 | A |
5535771 | Purdy et al. | Jul 1996 | A |
5535785 | Werge et al. | Jul 1996 | A |
5540661 | Tomisaka et al. | Jul 1996 | A |
5549566 | Elias et al. | Aug 1996 | A |
5549577 | Siegel et al. | Aug 1996 | A |
5549651 | Lynn | Aug 1996 | A |
D373633 | La Motte | Sep 1996 | S |
5555908 | Edwards et al. | Sep 1996 | A |
5556388 | Johlin, Jr. | Sep 1996 | A |
5562632 | Davila et al. | Oct 1996 | A |
5569235 | Ross et al. | Oct 1996 | A |
5573516 | Tyner | Nov 1996 | A |
5577706 | King | Nov 1996 | A |
5578059 | Patzer | Nov 1996 | A |
5597536 | Mayer | Jan 1997 | A |
5674206 | Allton et al. | Jan 1997 | A |
5603706 | Wyatt et al. | Feb 1997 | A |
5609584 | Gettig et al. | Mar 1997 | A |
5616129 | Mayer | Apr 1997 | A |
5616130 | Mayer | Apr 1997 | A |
5617897 | Myers | Apr 1997 | A |
5620424 | Abramson | Apr 1997 | A |
5620434 | Brony | Apr 1997 | A |
5624414 | Boettger | Apr 1997 | A |
5632735 | Wyatt et al. | May 1997 | A |
5639810 | Smith, III et al. | Jun 1997 | A |
5645538 | Richmond | Jul 1997 | A |
5660205 | Epstein | Aug 1997 | A |
5669891 | Vaillancourt | Sep 1997 | A |
5676346 | Leinsing | Oct 1997 | A |
5685866 | Lopez | Nov 1997 | A |
5690612 | Lopez et al. | Nov 1997 | A |
5690865 | Kindt-Larsen et al. | Nov 1997 | A |
5694686 | Lopez | Dec 1997 | A |
5695466 | Lopez et al. | Dec 1997 | A |
5699821 | Paradis | Dec 1997 | A |
5700248 | Lopez | Dec 1997 | A |
5728751 | Patnaik | Mar 1998 | A |
5730418 | Feith et al. | Mar 1998 | A |
5738663 | Lopez | Apr 1998 | A |
5749861 | Guala et al. | May 1998 | A |
5769825 | Lynn | Jun 1998 | A |
5775671 | Cote, Sr. | Jul 1998 | A |
5776113 | Daugherty et al. | Jul 1998 | A |
5782816 | Werschmidt et al. | Jul 1998 | A |
5788215 | Ryan | Aug 1998 | A |
5797897 | Jepson et al. | Aug 1998 | A |
5806551 | Meloul et al. | Sep 1998 | A |
5806831 | Paradis | Sep 1998 | A |
5807348 | Zinger et al. | Sep 1998 | A |
D400263 | Shugart | Oct 1998 | S |
5817068 | Urrutia | Oct 1998 | A |
5817069 | Arnett | Oct 1998 | A |
5820601 | Mayer | Oct 1998 | A |
5833213 | Ryan | Nov 1998 | A |
5836923 | Mayer | Nov 1998 | A |
5839715 | Leinsing | Nov 1998 | A |
5843046 | Motisi et al. | Dec 1998 | A |
5846233 | Lilley et al. | Dec 1998 | A |
5865807 | Blake, III | Feb 1999 | A |
5873862 | Lopez | Feb 1999 | A |
5882348 | Winterton et al. | Mar 1999 | A |
5899888 | Jepson et al. | May 1999 | A |
5901942 | Lopez | May 1999 | A |
5911710 | Barry et al. | Jun 1999 | A |
5928204 | Lopez | Jul 1999 | A |
5935620 | Baudin | Aug 1999 | A |
5947954 | Bonaldo | Sep 1999 | A |
5954313 | Ryan | Sep 1999 | A |
5957898 | Jepson et al. | Sep 1999 | A |
5967490 | Pike | Oct 1999 | A |
5979868 | Wu et al. | Nov 1999 | A |
6009902 | Troiani et al. | Jan 2000 | A |
6019748 | Lopez | Feb 2000 | A |
6029946 | Doyle | Feb 2000 | A |
6036171 | Weinheimer et al. | Mar 2000 | A |
6039302 | Cote, Sr. et al. | Mar 2000 | A |
6048335 | Mayer | Apr 2000 | A |
6050978 | Orr et al. | Apr 2000 | A |
6063062 | Paradis | May 2000 | A |
6079432 | Paradis | Jun 2000 | A |
6089541 | Weinheier et al. | Jul 2000 | A |
6099511 | Devos et al. | Aug 2000 | A |
6113068 | Ryan | Sep 2000 | A |
6116571 | Hettinger | Sep 2000 | A |
6117114 | Paradis | Sep 2000 | A |
6132403 | Lopez | Oct 2000 | A |
6132404 | Lopez | Oct 2000 | A |
6142446 | Leinsing | Nov 2000 | A |
6152900 | Mayer | Nov 2000 | A |
6162206 | Bindokas et al. | Dec 2000 | A |
6162251 | Kredovski | Dec 2000 | A |
6168137 | Paradis | Jan 2001 | B1 |
6170800 | Meloul et al. | Jan 2001 | B1 |
6171287 | Lynn | Jan 2001 | B1 |
6177037 | Mayer | Jan 2001 | B1 |
6183448 | Mayer | Feb 2001 | B1 |
6189859 | Rohrbough et al. | Feb 2001 | B1 |
D438955 | Rudzena | Mar 2001 | S |
6206861 | Mayer | Mar 2001 | B1 |
6210624 | Mayer | Apr 2001 | B1 |
6213996 | Jepson et al. | Apr 2001 | B1 |
6228065 | Lynn | May 2001 | B1 |
6228069 | Barth et al. | May 2001 | B1 |
6245048 | Fangrow et al. | Jun 2001 | B1 |
6254579 | Cogger et al. | Jul 2001 | B1 |
6261282 | Jepson et al. | Jul 2001 | B1 |
6261630 | Nazarova et al. | Jul 2001 | B1 |
6279783 | Brown et al. | Aug 2001 | B1 |
6290206 | Doyle | Sep 2001 | B1 |
6299131 | Ryan | Oct 2001 | B1 |
6299132 | Wienheimer | Oct 2001 | B1 |
6325782 | Lopez | Dec 2001 | B1 |
D454637 | Netenborg | Mar 2002 | S |
6364861 | Feith et al. | Apr 2002 | B1 |
6364869 | Bonaldo | Apr 2002 | B1 |
6390130 | Guala | May 2002 | B1 |
6428520 | Lopez et al. | Aug 2002 | B1 |
6444324 | Yang et al. | Sep 2002 | B1 |
6482188 | Rogers et al. | Nov 2002 | B1 |
D468015 | Horppu | Dec 2002 | S |
D468016 | Mosler et al. | Dec 2002 | S |
6541802 | Doyle | Apr 2003 | B2 |
6543745 | Enerson | Apr 2003 | B1 |
D475795 | Johnson et al. | Jun 2003 | S |
6572592 | Lopez | Jun 2003 | B1 |
6585229 | Cote, Sr. et al. | Jul 2003 | B2 |
6595964 | Finley et al. | Jul 2003 | B2 |
6595981 | Huet | Jul 2003 | B2 |
6599273 | Lopez | Jul 2003 | B1 |
6605076 | Jepson et al. | Aug 2003 | B1 |
6609696 | Enerson | Aug 2003 | B2 |
6635044 | Lopez | Oct 2003 | B2 |
6651956 | Miller | Nov 2003 | B2 |
6656517 | Michal et al. | Dec 2003 | B2 |
6669673 | Lopez | Dec 2003 | B2 |
6669681 | Jepson et al. | Dec 2003 | B2 |
6673053 | Wang et al. | Jan 2004 | B2 |
6682509 | Lopez | Jan 2004 | B2 |
6689109 | Lynn | Feb 2004 | B2 |
6695817 | Fangrow, Jr. | Feb 2004 | B1 |
6706022 | Leinsing et al. | Mar 2004 | B1 |
6712791 | Lui et al. | Mar 2004 | B2 |
6727294 | Kanayama et al. | Apr 2004 | B2 |
6740063 | Lynn | May 2004 | B2 |
6745998 | Doyle | Jun 2004 | B2 |
6755391 | Newton et al. | Jun 2004 | B2 |
6758833 | Lopez | Jul 2004 | B2 |
6783709 | Harreld et al. | Aug 2004 | B2 |
6802490 | Leinsing | Oct 2004 | B2 |
6808161 | Hishikawa | Oct 2004 | B1 |
6840501 | Doyle | Jan 2005 | B2 |
6848139 | Simon et al. | Feb 2005 | B2 |
6866656 | Tingey et al. | Mar 2005 | B2 |
6869426 | Ganem | Mar 2005 | B2 |
6871838 | Raines et al. | Mar 2005 | B2 |
6883778 | Newton et al. | Apr 2005 | B1 |
6892998 | Newton | May 2005 | B2 |
6908459 | Harding et al. | Jun 2005 | B2 |
6916309 | Fangrow, Jr. | Jul 2005 | B2 |
6932795 | Lopez et al. | Aug 2005 | B2 |
6964406 | Doyle | Nov 2005 | B2 |
6991215 | Kiehne | Jan 2006 | B2 |
6994315 | Ryan et al. | Feb 2006 | B2 |
6997917 | Niedospial, Jr. et al. | Feb 2006 | B2 |
7014169 | Newton et al. | Mar 2006 | B2 |
7025744 | Utterberg et al. | Apr 2006 | B2 |
7033339 | Lynn | Apr 2006 | B1 |
7037302 | Vaillancourt | May 2006 | B2 |
7044441 | Doyle | May 2006 | B2 |
7074216 | Fowles et al. | Jul 2006 | B2 |
7100890 | Cote et al. | Sep 2006 | B2 |
7104520 | Leinsing et al. | Sep 2006 | B2 |
7114701 | Peppel | Oct 2006 | B2 |
7125396 | Leinsing et al. | Oct 2006 | B2 |
7140592 | Phillips et al. | Nov 2006 | B2 |
7184825 | Leinsing et al. | Feb 2007 | B2 |
D546946 | Blake | Jul 2007 | S |
7244249 | Leinsing et al. | Jul 2007 | B2 |
7252652 | Moorehead et al. | Aug 2007 | B2 |
7264859 | Souns et al. | Sep 2007 | B2 |
D557281 | Miller et al. | Dec 2007 | S |
D557283 | Miller et al. | Dec 2007 | S |
7306197 | Parrino et al. | Dec 2007 | B2 |
7306199 | Leinsing et al. | Dec 2007 | B2 |
7314061 | Peppel | Jan 2008 | B2 |
7326188 | Russell et al. | Feb 2008 | B1 |
7329249 | Bonaldo | Feb 2008 | B2 |
7335182 | Hilaire | Feb 2008 | B1 |
7357792 | Newton et al. | Apr 2008 | B2 |
7396348 | Newton et al. | Jul 2008 | B2 |
7422369 | Bergman et al. | Sep 2008 | B2 |
D570880 | Miller et al. | Oct 2008 | S |
7470261 | Lynn | Dec 2008 | B2 |
7470262 | Hiejima et al. | Dec 2008 | B2 |
7497848 | Leinsing et al. | Mar 2009 | B2 |
7497849 | Fangrow, Jr. | Mar 2009 | B2 |
7510545 | Peppel | Mar 2009 | B2 |
7520489 | Rushke | Apr 2009 | B2 |
7530546 | Ryan et al. | May 2009 | B2 |
7533696 | Paul, Jr. | May 2009 | B2 |
7556060 | Guala | Jul 2009 | B2 |
7559530 | Korogi et al. | Jul 2009 | B2 |
7563243 | Mendels | Jul 2009 | B2 |
7581561 | Funamura et al. | Sep 2009 | B2 |
7584767 | Funamura et al. | Sep 2009 | B2 |
7588563 | Guala | Sep 2009 | B2 |
7591449 | Raines et al. | Sep 2009 | B2 |
7601141 | Dikeman et al. | Oct 2009 | B2 |
7615035 | Peppel | Nov 2009 | B2 |
7624749 | Guala | Dec 2009 | B2 |
7628774 | Fangrow, Jr. | Dec 2009 | B2 |
7645274 | Whitley | Jan 2010 | B2 |
7651481 | Raybuck | Jan 2010 | B2 |
7666170 | Guala | Feb 2010 | B2 |
7673653 | Mijers et al. | Mar 2010 | B2 |
7703486 | Costanzo | Apr 2010 | B2 |
7713250 | Harding et al. | May 2010 | B2 |
7717882 | Harding | May 2010 | B2 |
7717886 | Lopez | May 2010 | B2 |
7743799 | Mosler et al. | Jun 2010 | B2 |
7753338 | Desecki | Jul 2010 | B2 |
7753892 | Newton et al. | Jul 2010 | B2 |
7758566 | Simpson et al. | Jul 2010 | B2 |
7763013 | Baldwin et al. | Jul 2010 | B2 |
7763199 | Fangrow | Jul 2010 | B2 |
7771383 | Truitt et al. | Aug 2010 | B2 |
7784766 | Guala | Aug 2010 | B2 |
7815168 | Vangsness et al. | Oct 2010 | B2 |
7824393 | Fangrow, Jr. | Nov 2010 | B2 |
7837658 | Cote, Sr. et al. | Nov 2010 | B2 |
7841581 | Thorne, Jr. et al. | Nov 2010 | B2 |
7842026 | Cahill et al. | Nov 2010 | B2 |
7857284 | Kimball et al. | Dec 2010 | B2 |
7857285 | Lee et al. | Dec 2010 | B2 |
7857802 | Brandenburger et al. | Dec 2010 | B2 |
7857805 | Raines | Dec 2010 | B2 |
7862537 | Zinger et al. | Jan 2011 | B2 |
7867204 | Bartholomew et al. | Jan 2011 | B2 |
7879012 | Kane et al. | Feb 2011 | B2 |
7900659 | Whitley et al. | Mar 2011 | B2 |
7905873 | Rondeau et al. | Mar 2011 | B2 |
7909056 | Truitt et al. | Mar 2011 | B2 |
7914502 | Newton et al. | Mar 2011 | B2 |
D638933 | Hill | May 2011 | S |
7947032 | Harding et al. | May 2011 | B2 |
7954515 | Gerst | Jun 2011 | B2 |
7975722 | Kiehne | Jul 2011 | B2 |
7981090 | Plishka et al. | Jul 2011 | B2 |
7981381 | Lurvey et al. | Jul 2011 | B2 |
7984730 | Ziv et al. | Jul 2011 | B2 |
D643920 | Gil Pascual | Aug 2011 | S |
7988128 | Wentling | Aug 2011 | B2 |
7993328 | Whitley | Aug 2011 | B2 |
7998134 | Fangrow | Aug 2011 | B2 |
8006953 | Bennett | Aug 2011 | B2 |
D644731 | Fangrow, Jr. | Sep 2011 | S |
8015990 | Pascal et al. | Sep 2011 | B2 |
8021354 | Huang | Sep 2011 | B2 |
8034021 | Mendels | Oct 2011 | B2 |
8034035 | Weaver et al. | Oct 2011 | B2 |
8038663 | Miner | Oct 2011 | B2 |
8042838 | Buckler et al. | Oct 2011 | B2 |
8048038 | Guala | Nov 2011 | B2 |
8062266 | McKinnon et al. | Nov 2011 | B2 |
8062267 | McKinnon et al. | Nov 2011 | B2 |
8062280 | Jepson et al. | Nov 2011 | B2 |
8066648 | Mark | Nov 2011 | B1 |
8066669 | Christensen et al. | Nov 2011 | B2 |
8066670 | Cluff et al. | Nov 2011 | B2 |
8070189 | Yow et al. | Dec 2011 | B2 |
8070725 | Christensen | Dec 2011 | B2 |
8074964 | Mansour et al. | Dec 2011 | B2 |
8096525 | Ryan | Jan 2012 | B2 |
8100868 | Newton et al. | Jan 2012 | B2 |
8100869 | Vangsness et al. | Jan 2012 | B2 |
8105314 | Fangrow | Jan 2012 | B2 |
D654166 | Lair | Feb 2012 | S |
D655000 | Mirigian | Feb 2012 | S |
8123738 | Vaillancourt | Feb 2012 | B2 |
8133209 | Guala | Mar 2012 | B2 |
8136330 | Ostler et al. | Mar 2012 | B2 |
8137303 | Stout et al. | Mar 2012 | B2 |
8142403 | Carlyon | Mar 2012 | B2 |
8152790 | Lopez et al. | Apr 2012 | B2 |
8156971 | Costanzo | Apr 2012 | B2 |
8162006 | Guala | Apr 2012 | B2 |
8162013 | Rosenquist et al. | Apr 2012 | B2 |
8162914 | Kraushaar et al. | Apr 2012 | B2 |
8167863 | Yow | May 2012 | B2 |
8172823 | Rondeau et al. | May 2012 | B2 |
8177760 | Rome et al. | May 2012 | B2 |
8177768 | Leinsing | May 2012 | B2 |
8177772 | Christensen et al. | May 2012 | B2 |
8182452 | Mansourt et al. | May 2012 | B2 |
8197452 | Harding et al. | Jun 2012 | B2 |
8197466 | Yokota et al. | Jun 2012 | B2 |
8211089 | Winsor et al. | Jul 2012 | B2 |
8221363 | Jepson | Jul 2012 | B2 |
8221391 | Fangrow, Jr. | Jul 2012 | B2 |
8241268 | Whitley | Aug 2012 | B2 |
8277424 | Pan | Oct 2012 | B2 |
8286657 | Belley et al. | Oct 2012 | B2 |
8286936 | Kitani et al. | Oct 2012 | B2 |
8287518 | Kitani et al. | Oct 2012 | B2 |
8298195 | Peppel | Oct 2012 | B2 |
8298196 | Mansour | Oct 2012 | B1 |
8337483 | Harding et al. | Dec 2012 | B2 |
8361408 | Lynn | Jan 2013 | B2 |
8366658 | Davis et al. | Feb 2013 | B2 |
8366676 | Harding et al. | Feb 2013 | B2 |
8372043 | Grimm et al. | Feb 2013 | B2 |
8377010 | Harding et al. | Feb 2013 | B2 |
8382741 | Chelak | Feb 2013 | B2 |
8398598 | Carlyon et al. | Mar 2013 | B2 |
8398607 | Fangrow, Jr. | Mar 2013 | B2 |
8403886 | Bialecki et al. | Mar 2013 | B2 |
8403894 | Lynn et al. | Mar 2013 | B2 |
8403905 | Yow | Mar 2013 | B2 |
8408226 | Raines et al. | Apr 2013 | B2 |
8409164 | Fangrow | Apr 2013 | B2 |
8409165 | Niedospial, Jr. et al. | Apr 2013 | B2 |
8414542 | Stroup | Apr 2013 | B2 |
8439880 | Rondeau | May 2013 | B2 |
8444628 | Fangrow, Jr. | May 2013 | B2 |
8454579 | Fangrow, Jr. | Jun 2013 | B2 |
8529524 | Newton et al. | Sep 2013 | B2 |
8628515 | Fangrow, Jr. et al. | Jan 2014 | B2 |
8636720 | Truitt et al. | Jan 2014 | B2 |
8640725 | Truitt et al. | Feb 2014 | B2 |
8671964 | Py | Mar 2014 | B2 |
8679090 | Anderson et al. | Mar 2014 | B2 |
8684994 | Lev et al. | Apr 2014 | B2 |
8701696 | Guala | Apr 2014 | B2 |
8702675 | Imai | Apr 2014 | B2 |
8715222 | Truitt et al. | May 2014 | B2 |
8715247 | Mansour et al. | May 2014 | B2 |
8721627 | Albert | May 2014 | B2 |
D707355 | Bow | Jun 2014 | S |
8747370 | Feith et al. | Jun 2014 | B2 |
8758306 | Lopez et al. | Jun 2014 | B2 |
8801678 | Panian et al. | Aug 2014 | B2 |
8834432 | Winsor et al. | Sep 2014 | B2 |
8840577 | Zollinger et al. | Sep 2014 | B1 |
8864725 | Ranalletta et al. | Oct 2014 | B2 |
8870846 | Davis et al. | Oct 2014 | B2 |
8876784 | Cote, Sr. et al. | Nov 2014 | B2 |
8882742 | Dikeman et al. | Nov 2014 | B2 |
8910919 | Bonnal et al. | Dec 2014 | B2 |
8951233 | Mansour | Feb 2015 | B2 |
8968261 | Kimball et al. | Mar 2015 | B2 |
8968271 | Guala | Mar 2015 | B2 |
8974425 | Tachizaki et al. | Mar 2015 | B2 |
8979804 | Ho et al. | Mar 2015 | B2 |
9017295 | Pan | Apr 2015 | B2 |
9032997 | Abura et al. | May 2015 | B2 |
9039047 | Imai | May 2015 | B2 |
9044585 | Masuda et al. | Jun 2015 | B2 |
9061130 | Truitt et al. | Jun 2015 | B2 |
9067049 | Panian et al. | Jun 2015 | B2 |
D734456 | Cromett | Jul 2015 | S |
9089680 | Ueda et al. | Jul 2015 | B2 |
9089681 | Ueda et al. | Jul 2015 | B2 |
9089682 | Yeh et al. | Jul 2015 | B2 |
D737436 | Lev | Aug 2015 | S |
9108034 | Winsor | Aug 2015 | B2 |
9114244 | Yeh et al. | Aug 2015 | B2 |
9119950 | Mansour et al. | Sep 2015 | B2 |
9138572 | Zeytoonian et al. | Sep 2015 | B2 |
9144672 | Mansour et al. | Sep 2015 | B2 |
9162029 | Zollinger | Oct 2015 | B2 |
9192753 | Lopez et al. | Nov 2015 | B2 |
9198831 | Rogers | Dec 2015 | B2 |
9205243 | Lopez et al. | Dec 2015 | B2 |
9212772 | Ho et al. | Dec 2015 | B2 |
9220882 | Belley et al. | Dec 2015 | B2 |
9234616 | Carrez et al. | Jan 2016 | B2 |
9238128 | Yamaguchi et al. | Jan 2016 | B2 |
9278205 | Quach et al. | Mar 2016 | B2 |
9278206 | Fangrow et al. | Mar 2016 | B2 |
9289588 | Chen | Mar 2016 | B2 |
D753283 | Efinger | Apr 2016 | S |
9314604 | Bonnal et al. | Apr 2016 | B2 |
9345641 | Krause et al. | May 2016 | B2 |
9352086 | Guala | May 2016 | B2 |
9370466 | Garfield et al. | Jun 2016 | B2 |
9370651 | Zollinger et al. | Jun 2016 | B2 |
9375559 | Feith et al. | Jun 2016 | B2 |
9381339 | Wu et al. | Jul 2016 | B2 |
9393398 | Truitt et al. | Jul 2016 | B2 |
9409007 | Yeh | Aug 2016 | B2 |
9421354 | Carmody et al. | Aug 2016 | B2 |
9433708 | Eddy | Sep 2016 | B2 |
D786427 | Nelson | May 2017 | S |
D793551 | Nelson | Aug 2017 | S |
20010049508 | Fangrow, Jr. | Dec 2001 | A1 |
20020120333 | Keogh et al. | Aug 2002 | A1 |
20040006330 | Fangrow, Jr. | Jan 2004 | A1 |
20050020981 | Kurth | Jan 2005 | A1 |
20050059952 | Giuliano et al. | Mar 2005 | A1 |
20050121638 | Doyle | Jun 2005 | A1 |
20050222541 | Lopez et al. | Oct 2005 | A1 |
20060004331 | Fangrow, Jr. | Jan 2006 | A1 |
20060161115 | Fangrow, Jr. | Jul 2006 | A1 |
20060200088 | Lopez | Sep 2006 | A1 |
20060200089 | Lopez et al. | Sep 2006 | A1 |
20060200090 | Lopez et al. | Sep 2006 | A1 |
20060206061 | Lopez et al. | Sep 2006 | A1 |
20060211997 | Fangrow, Jr. | Sep 2006 | A1 |
20060211998 | Fangrow, Jr. | Sep 2006 | A1 |
20060211999 | Fangrow, Jr. | Sep 2006 | A1 |
20060212001 | Fangrow, Jr. | Sep 2006 | A1 |
20060212003 | Fangrow, Jr. | Sep 2006 | A1 |
20060212006 | Fangrow, Jr. | Sep 2006 | A1 |
20060224127 | Fangrow, Jr. | Oct 2006 | A1 |
20060264842 | Fangrow, Jr. | Nov 2006 | A1 |
20060264844 | Fangrow, Jr. | Nov 2006 | A1 |
20060264849 | Lopez et al. | Nov 2006 | A1 |
20060264909 | Fangrow, Jr. | Nov 2006 | A1 |
20060264910 | Fangrow, Jr. | Nov 2006 | A1 |
20060270999 | Fangrow, Jr. | Nov 2006 | A1 |
20060271016 | Fangrow, Jr. | Nov 2006 | A1 |
20060276757 | Fangrow, Jr. | Dec 2006 | A1 |
20060276758 | Fangrow, Jr. | Dec 2006 | A1 |
20070100284 | Leinsing et al. | May 2007 | A1 |
20070106205 | Connell et al. | May 2007 | A1 |
20070112312 | Fangrow, Jr. | May 2007 | A1 |
20070112313 | Fangrow, Jr. | May 2007 | A1 |
20070224865 | Fangrow, Jr. | Sep 2007 | A1 |
20070225425 | Nash et al. | Sep 2007 | A1 |
20070235676 | Vangsness et al. | Oct 2007 | A1 |
20070254000 | Guo et al. | Nov 2007 | A1 |
20070270756 | Peppel et al. | Nov 2007 | A1 |
20080039802 | Vangsness et al. | Feb 2008 | A1 |
20080086097 | Rasmussen et al. | Apr 2008 | A1 |
20080086099 | McKinnon et al. | Apr 2008 | A1 |
20080097407 | Plishka | Apr 2008 | A1 |
20080249508 | Lopez et al. | Oct 2008 | A1 |
20090005761 | Guala | Jan 2009 | A1 |
20090087606 | Julien | Apr 2009 | A1 |
20090198209 | Usher et al. | Aug 2009 | A1 |
20090209922 | Boisjoly | Aug 2009 | A1 |
20090292252 | Lareau et al. | Nov 2009 | A1 |
20100030163 | Carrez et al. | Feb 2010 | A1 |
20100030164 | Kimball et al. | Feb 2010 | A1 |
20100036330 | Plishka et al. | Feb 2010 | A1 |
20100059474 | Brandenburger et al. | Mar 2010 | A1 |
20100059702 | Mansour et al. | Mar 2010 | A1 |
20100063456 | Rahimy et al. | Mar 2010 | A1 |
20100063482 | Mansour | Mar 2010 | A1 |
20100108681 | Jepson et al. | May 2010 | A1 |
20100152680 | Memahon | Jun 2010 | A1 |
20100174242 | Anderson et al. | Jul 2010 | A1 |
20100241088 | Ranalletta et al. | Sep 2010 | A1 |
20100249723 | Fangrow, Jr. | Sep 2010 | A1 |
20100249724 | Cote, Sr. et al. | Sep 2010 | A1 |
20100249725 | Cote, Sr. et al. | Sep 2010 | A1 |
20100264343 | Jeory | Oct 2010 | A1 |
20100270792 | Lauer | Oct 2010 | A1 |
20100283238 | Deighan et al. | Nov 2010 | A1 |
20100292673 | Korogi et al. | Nov 2010 | A1 |
20100292674 | Jepson et al. | Nov 2010 | A1 |
20100300556 | Carmody et al. | Dec 2010 | A1 |
20100324502 | Guala | Dec 2010 | A1 |
20110004183 | Carrez et al. | Jan 2011 | A1 |
20110024664 | Burnard et al. | Feb 2011 | A1 |
20110028914 | Mansour et al. | Feb 2011 | A1 |
20110028915 | Siopes et al. | Feb 2011 | A1 |
20110046572 | Fangrow | Feb 2011 | A1 |
20110048540 | Stroup | Mar 2011 | A1 |
20110054440 | Lewis | Mar 2011 | A1 |
20110060293 | Guala | Mar 2011 | A1 |
20110087164 | Mosler et al. | Apr 2011 | A1 |
20110106046 | Hiranuma et al. | May 2011 | A1 |
20110125104 | Lynn | May 2011 | A1 |
20110130717 | David et al. | Jun 2011 | A1 |
20110130724 | Mansour et al. | Jun 2011 | A1 |
20110130726 | Crawford et al. | Jun 2011 | A1 |
20110130727 | Crawford et al. | Jun 2011 | A1 |
20110130728 | McKinnon | Jun 2011 | A1 |
20110152832 | Foshee et al. | Jun 2011 | A1 |
20110166532 | Brandenburger et al. | Jul 2011 | A1 |
20110178493 | Okiyama | Jul 2011 | A1 |
20110257590 | Winsor et al. | Oct 2011 | A1 |
20110264037 | Foshee et al. | Oct 2011 | A1 |
20110266477 | Stroup | Nov 2011 | A1 |
20110275988 | Davis et al. | Nov 2011 | A1 |
20110276010 | Davis et al. | Nov 2011 | A1 |
20110276031 | Hoang et al. | Nov 2011 | A1 |
20110295235 | Fangrow | Dec 2011 | A1 |
20110306940 | Miyasaka | Dec 2011 | A1 |
20110319821 | Kitani et al. | Dec 2011 | A1 |
20110319859 | Zeytoonian et al. | Dec 2011 | A1 |
20120013121 | Weckstrom | Jan 2012 | A1 |
20120022469 | Alpert | Jan 2012 | A1 |
20120042971 | Py | Feb 2012 | A1 |
20120046636 | Kriheli | Feb 2012 | A1 |
20120053529 | Imai | Mar 2012 | A1 |
20120059314 | Eichhorst | Mar 2012 | A1 |
20120059334 | Pan | Mar 2012 | A1 |
20120059346 | Sheppard et al. | Mar 2012 | A1 |
20120065626 | Naftalovitz et al. | Mar 2012 | A1 |
20120095407 | Chebator et al. | Apr 2012 | A1 |
20120109077 | Ryan | May 2012 | A1 |
20120130305 | Bonnal et al. | May 2012 | A1 |
20120130352 | Naftalovitz et al. | May 2012 | A1 |
20120150129 | Jin et al. | Jun 2012 | A1 |
20120153201 | Larose et al. | Jun 2012 | A1 |
20120157928 | Mermet | Jun 2012 | A1 |
20120157933 | Newton et al. | Jun 2012 | A1 |
20120179108 | Delabie | Jul 2012 | A1 |
20120192968 | Bonnal et al. | Aug 2012 | A1 |
20120209238 | Rosenquist et al. | Aug 2012 | A1 |
20120215182 | Mansour et al. | Aug 2012 | A1 |
20120220955 | Maseda et al. | Aug 2012 | A1 |
20120220977 | Yow | Aug 2012 | A1 |
20120220984 | Christensen et al. | Aug 2012 | A1 |
20120245564 | Tekeste et al. | Sep 2012 | A1 |
20120259292 | Koehler | Oct 2012 | A1 |
20120316514 | Mansour | Dec 2012 | A1 |
20120316536 | Carrez et al. | Dec 2012 | A1 |
20120323063 | Costanzo | Dec 2012 | A1 |
20120330277 | Winsor et al. | Dec 2012 | A1 |
20130012870 | Dikeman et al. | Jan 2013 | A1 |
20130030386 | Panian et al. | Jan 2013 | A1 |
20130035668 | Kitani et al. | Feb 2013 | A1 |
20130046315 | Woehr et al. | Feb 2013 | A1 |
20130053815 | Mucientes et al. | Feb 2013 | A1 |
20130060205 | Mansour et al. | Mar 2013 | A1 |
20130066293 | Garfield et al. | Mar 2013 | A1 |
20130079730 | Mosler et al. | Mar 2013 | A1 |
20130138075 | Lambert | May 2013 | A1 |
20130253478 | Fangrow, Jr. | Sep 2013 | A1 |
20130289534 | Fangrow, Jr. | Oct 2013 | A1 |
20130331800 | Newton et al. | Dec 2013 | A1 |
20140031765 | Siopes et al. | Jan 2014 | A1 |
20140135709 | Zollinger | May 2014 | A1 |
20140142519 | Truitt et al. | May 2014 | A1 |
20140155836 | Truitt et al. | Jun 2014 | A1 |
20140174578 | Bonnal et al. | Jun 2014 | A1 |
20140180219 | Ho et al. | Jun 2014 | A1 |
20140180258 | Ho et al. | Jun 2014 | A1 |
20140209197 | Carrez et al. | Jul 2014 | A1 |
20140257198 | Truitt et al. | Sep 2014 | A1 |
20140261860 | Heath et al. | Sep 2014 | A1 |
20140276455 | Yeh et al. | Sep 2014 | A1 |
20140276456 | Eddy | Sep 2014 | A1 |
20140276458 | Mansour et al. | Sep 2014 | A1 |
20140276459 | Yeh et al. | Sep 2014 | A1 |
20140276463 | Mansour et al. | Sep 2014 | A1 |
20140276466 | Yeh et al. | Sep 2014 | A1 |
20140296794 | Li | Oct 2014 | A1 |
20140303602 | Mansour et al. | Oct 2014 | A1 |
20140316350 | Yamaguchi et al. | Oct 2014 | A1 |
20140358033 | Lynn | Dec 2014 | A1 |
20140371686 | Sano et al. | Dec 2014 | A1 |
20150040987 | Reichert et al. | Feb 2015 | A1 |
20150040988 | Reichert et al. | Feb 2015 | A1 |
20150045746 | Macy, Jr. et al. | Feb 2015 | A1 |
20150045772 | Reichert et al. | Feb 2015 | A1 |
20150126942 | Lopez et al. | May 2015 | A1 |
20150148756 | Lynn | May 2015 | A1 |
20150151100 | Mansour | Jun 2015 | A1 |
20150157799 | Chen et al. | Jun 2015 | A1 |
20150157800 | Chen et al. | Jun 2015 | A1 |
20150157848 | Wu et al. | Jun 2015 | A1 |
20150176715 | Huang et al. | Jun 2015 | A1 |
20150190627 | Ueda et al. | Jul 2015 | A1 |
20150196749 | Ziv et al. | Jul 2015 | A1 |
20150196750 | Ueda et al. | Jul 2015 | A1 |
20150202424 | Harton | Jul 2015 | A1 |
20150258325 | Panian et al. | Sep 2015 | A1 |
20150265827 | Keyser et al. | Sep 2015 | A1 |
20150265829 | Truitt et al. | Sep 2015 | A1 |
20150297817 | Guala | Oct 2015 | A1 |
20150297880 | Ogawa et al. | Oct 2015 | A1 |
20150313523 | Chelak et al. | Nov 2015 | A1 |
20150374910 | Mansour | Dec 2015 | A1 |
20160000364 | Mendels et al. | Jan 2016 | A1 |
20160001057 | Lopez et al. | Jan 2016 | A1 |
20160015958 | Ueda et al. | Jan 2016 | A1 |
20160015960 | Bonnal | Jan 2016 | A1 |
20160015961 | Mansour et al. | Jan 2016 | A1 |
20160022977 | Ueda et al. | Jan 2016 | A1 |
20160022978 | Ueda | Jan 2016 | A1 |
20160030730 | Mosler et al. | Feb 2016 | A1 |
20160038730 | Zollinger | Feb 2016 | A1 |
20160089492 | Burnard et al. | Mar 2016 | A1 |
20160089529 | Bolz et al. | Mar 2016 | A1 |
20160114147 | Siopes et al. | Apr 2016 | A1 |
20160129235 | Ryan | May 2016 | A1 |
20160136051 | Lavi | May 2016 | A1 |
20160144110 | Ueda | May 2016 | A1 |
20160158524 | Quach et al. | Jun 2016 | A1 |
20160235961 | Maffei | Aug 2016 | A1 |
20160317798 | Lopez et al. | Nov 2016 | A1 |
Number | Date | Country |
---|---|---|
1 105 959 | Jul 1981 | CA |
2 149 725 | Nov 1995 | CA |
2 175 021 | Nov 1996 | CA |
636526 | Jun 1983 | CH |
670955 | Jul 1989 | CH |
855 319 | Sep 1952 | DE |
84 25 197.2 | Sep 1985 | DE |
37 40 269 | Jun 1989 | DE |
0 263 789 | Apr 1988 | EP |
0 309 771 | Apr 1989 | EP |
0 399 119 | Nov 1990 | EP |
0 446 463 | Sep 1991 | EP |
2 000 685 | Jan 1979 | GB |
2 001 146 | Jan 1979 | GB |
2 034 185 | Jun 1980 | GB |
WO 199220736 | Nov 1992 | WO |
WO 199959672 | Nov 1999 | WO |
WO 199961093 | Dec 1999 | WO |
WO 2003018104 | Mar 2003 | WO |
WO 2005115521 | Aug 2005 | WO |
WO 2006013433 | Feb 2006 | WO |
WO 2006062912 | Jun 2006 | WO |
WO 2008048777 | Apr 2008 | WO |
WO 2009052433 | Apr 2009 | WO |
WO 2009111596 | Sep 2009 | WO |
WO 2010004471 | Jan 2010 | WO |
Entry |
---|
U.S. Appl. No. 29/510,851, filed Dec. 3, 2014, Nelson. |
U.S. Appl. No. 29/510,852, filed Dec. 3, 2014, Nelson. |
U.S. Appl. No. 14/961,163, filed Dec. 7, 2015, Lopez et al. |
“Faulding Inc. receives FDA permission to market patented Safe-Connect Valve”, dated Dec. 2, 1996. |
BD Medical: Needleless IV Access Devices, one page, 2007. |
Capless Backcheck Valve, dated Sep. 3, 1993, in 2 pages. |
CardinalHealth, SmartSite Brochure: “SmartSite® Disposables,” 2004, in 12 pages. |
CareFusion, Medegen Introduces MaxPlus® Clear, First and Only Clear Positive Displacement Connector for Use in Infusion Therapy, MaxGuard News, one page article, dated Mar. 10, 2008—Ontario, CA. |
Caresite™ Luer Access Device, dated 2010, in 2 pages. |
Clearlink, needleless IV access system, Baxter 2007 brochure, in 2 pages. |
F.D.A. 510(k) Summary of Safety and Effectiveness, dated Nov. 17, 1997, in 5 pages. |
LifeShield TKO Anti-Reflux Device Brochure, appears to contain a date of Feb. 8, in 8 pages. |
MEDI-4955 Liquid Silicone Rubber from NuSil Silicone Technology, dated Dec. 17, 2010, in 2 pages. |
MicroClave Connector Brochure. The MicroClave was available before Mar. 25, 2008, in 2 pages. |
MicroClave Neutral Displacement Connector A Neddlefree Closed System Device. Brochure Sep. 24, 2008, in 2 pages. |
MicroClave Product Page Video Shots. Sep. 24, 2008, in 2 pages. |
Nexus Medical Nexus TKO, appears to contain a date of Mar. 2006, in 6 pages. |
PASV Valve Connector Brochure, which appears to be at least as early as Feb. 20, 2001, in 2 pages. |
Saechtling Tworzywa Sztuczne, (with English translation) WN-T Warszawa, 1999, V edition, pp. 224-225. |
U.S. Appl. No. 29/603,008, filed May 5, 2017, Nelson. |
U.S. Appl. No. 29/611,987, filed Jul. 27, 2017, Nelson. |
Number | Date | Country | |
---|---|---|---|
20160279404 A1 | Sep 2016 | US |
Number | Date | Country | |
---|---|---|---|
61914892 | Dec 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2014/068455 | Dec 2014 | US |
Child | 15179760 | US |